S1PR1 and myeloid sarcoma: Phosphorylated fingolimod acts as a functional S1PR1 and S1PR3 – S1PR5 antagonist, internalizing the S1PR1 on lymphocytes, sequestering them within the lymph nodes, and preventing their infiltration within the CNS, the main mechanism of action in MS [30,37].